Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In these activities, 6 experts review the rationale for ADCs used alone and in combination with immune checkpoint inhibitors, review recent data supporting the use of ADCs, and review cases in a panel-style discussion of patients with TNBC.
Target Audience
This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanistic rationale for utilizing ADCs to target TROP2 in the management of patients with metastatic TNBC
- Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC
- Apply effective methods mitigating adverse effects associated with ADCs in patients with metastatic TNBC
- Evaluate recent evidence supporting the evolving role of ADCs in the management of patients with metastatic TNBC